FDA Criticizes UniQure's Huntington’s Disease Drug Amid Growing Tensions

The FDA's recent critique of UniQure’s Huntington’s disease treatment marks a significant escalation in regulatory scrutiny, potentially hindering the biotech firm’s progress. This tension signals a challenging environment for gene therapy approvals and could impact investor confidence. Moving forward, monitoring FDA's comments and UniQure's response will be crucial for stakeholders and the future of Huntington’s treatments.